{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"024-223-210-314-542","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"024-223-210-314-542"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":11845,"type":"PATENT","title":"University of Kentucky Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":2985,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8457,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately:univ* AND Kentucky. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 2847
Search Applicants and Owners separately:univ* AND Kentucky. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 2847
inhibiting one or more of an inflammasome of the cell; MyD88 of the cell; IL-18 of the cell; VDAC1 of the cell; VDAC2 of the cell; caspase-8 of the cell; and NFκB of the cell;\n
wherein the cell is protected against Alu-RNA-induced degeneration;\n
wherein inhibiting the inflammasome consists essentially of administering an inflammasome inhibitor selected from the group consisting of an NLRP3 inhibitor, a PYCARD inhibitor, an inflammosome inhibitor comprising a sequence selected from the sequences of SEQ ID NOS: 7-16, an inhibitor of Caspase-1, a peptide inhibitor of Caspase-1, a Caspase-1 inhibitor comprising the sequence of SEQ ID NO: 17, and the inflammosome inhibitors selected from: ion channel inhibitors; IkB-α inhibitors; antibodies selected from: Anti-ASC, Anti-NALP1, antibodies based on protein sequences selected from: ASC: ALR QTQ PYL VTD LEQ S; NALP1: MEE SQS KEE SNT EG-cys; Anti-NALP1, anti-IL-1β, anti-IL-18, anti-caspase-1, and anti-caspase-11; direct inhibitors of Caspase-1 and/or NLRP3; parthenolide; estrogen binding B-box proteins, COP, ICEBERG, and Z-WEHD-FMK; Caspase 1 and/or 4 inhibitors; Caspase-12 inhibitors; host-derived inhibitors of caspase-1; inhibitors of Nlrp1b inflammasome; virus expressed inhibitors of the inflammasome; potassium chloride; Cathepsin-B-inhibitors; Cytochalsin D; ROS inhibitors; ASC-1 inhibitors; NLRP3 inflammasome pan-caspase inhibitors; Microtubules; an isolated double-stranded RNA molecule that inhibits expression of NLRP3, and which can be conjugated to cholesterol or not, and at least one strand including the sequence: GUUUGACUAUCUGUUCUdTdT (SEQ ID NO: 7); an isolated double-stranded RNA molecule that inhibits expression of PYCARD, at least one strand of which includes the sequence of: 5′-GAAGCUCUUCAGUUUCAdTdT-3′ (SEQ ID NO: 12); and an isolated double-stranded RNA molecule that inhibits expression of PYCARD, at least one strand of which includes a sequence selected from: 5′-GAAGCUCUUCAGUUUCAdTdT-3′ (SEQ ID NO: 12); 5′-GGCUGCUGGAUGCUCUGUACGGGAA-3′ (SEQ ID NO: 13); and 5′-UUCCCGUACAGAGCAUCCAGCAGCC-3′ (SEQ ID NO: 14)."],"number":1,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the inhibiting MyD88 comprises administering a MyD88 inhibitor."],"number":2,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 2, wherein the inhibitor is selected from the group consisting of a MyD88 inhibitor comprising a polypeptide sequence selected from the sequences of SEQ ID NO: 1, 54, 55, 60, and 61; and a MyD88 inhibitor comprising a double-stranded RNA molecule, at least one strand of which includes a sequence selected from SEQ ID NOS: 3, 4, 5, 6, and 56."],"number":3,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 2, wherein the My D88 inhibitor is selected from the group consisting of a MyD88 homodimerization inhibitor; Pepinh-MYD; a dominant negative or splice variant of MyD88; a MyD88 splice variants that lack exon 2; and MyD88 inhibitors as set forth in Table C."],"number":4,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 4, wherein the inhibitor is administered by intravitreous injection; subretinal injection; episcleral injection; sub-Tenon's injection; retrobulbar injection; peribulbar injection; topical eye drop application; release from a sustained release implant device that is sutured to or attached to or placed on the sclera, or injected into the vitreous humor, or injected into the anterior chamber, or implanted in the lens bag or capsule; oral administration; or intravenous administration."],"number":5,"annotation":false,"title":false,"claim":true},{"lines":["A method of protecting an RPE cell, a retinal photoreceptor cell, or a choroidal cell, comprising:\n
inhibiting one or more of an inflammasome of the cell; MyD88 of the cell; IL-18 of the cell; VDAC1 of the cell; VDAC2 of the cell; caspase-8 of the cell; and NFκB of the cell;\n
wherein the cell is protected against Alu-RNA-induced degeneration;\n
wherein inhibiting the inflammasome comprises administering an inflammasome inhibitor selected from the group consisting of an NLRP3 inhibitor, a PYCARD inhibitor, an inflammosome inhibitor comprising a sequence selected from the sequences of SEQ ID NOS: 7-16, an inhibitor of Caspase-1, a peptide inhibitor of Caspase-1, a Caspase-1 inhibitor comprising the sequence of SEQ ID NO: 17, and the inflammosome inhibitors selected from: ion channel inhibitors; IkB-α inhibitors; antibodies selected from: Anti-ASC, Anti-NALP1, antibodies based on protein sequences selected from: ASC: ALR QTQ PYL VTD LEQ S; NALP1: MEE SQS KEE SNT EG-cys; Anti-NALP1, anti-IL-1β, anti-IL-18, anti-caspase-1, and anti-caspase-11; direct inhibitors of Caspase-1 and/or NLRP3; parthenolide; estrogen binding B-box proteins, COP, ICEBERG, and Z-WEHD-FMK; Caspase 1 and/or 4 inhibitors; Caspase-12 inhibitors; host-derived inhibitors of caspase-1; inhibitors of Nlrp1b inflammasome; virus expressed inhibitors of the inflammasome; potassium chloride; Cathepsin-B-inhibitors; Cytochalsin D; ROS inhibitors; ASC-1 inhibitors; NLRP3 inflammasome pan-caspase inhibitors; Microtubules; an isolated double-stranded RNA molecule that inhibits expression of NLRP3, and which can be conjugated to cholesterol or not, and at least one strand including the sequence: GUUUGACUAUCUGUUCUdTdT (SEQ ID NO: 7); an isolated double-stranded RNA molecule that inhibits expression of PYCARD, at least one strand of which includes the sequence of: 5′-GAAGCUCUUCAGUUUCAdTdT-3′ (SEQ ID NO: 12); and an isolated double-stranded RNA molecule that inhibits expression of PYCARD, at least one strand of which includes a sequence selected from: 5′-GAAGCUCUUCAGUUUCAdTdT-3′ (SEQ ID NO: 12); 5′-GGCUGCUGGAUGCUCUGUACGGGAA-3′ (SEQ ID NO: 13); and 5′-UUCCCGUACAGAGCAUCCAGCAGCC-3′ (SEQ ID NO: 14), wherein the inflammasome includes a protein encoded by PYCARD."],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 6, wherein the inflammasome is selected from NLRP3 inflammasome, NLRP1 inflammasome, NLRC4 inflammasome, AIM2 inflammasome, and IFI16 inflammasome."],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 7, wherein the inflammasome is the NLRP3 inflammasome."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the inflammasome inhibitor is selected from glybenclamide/glyburide; BAY11-7082 (CAS Number: 195462-67-7; also known as (E)-3-(4-Methylphenylsulfonyl)-2-propenenitrile); Anti-ASC and Anti-NALP1 and antibodies based on protein sequences selected from: ASC: ALR QTQ PYL VTD LEQ S; NALP1: MEE SQS KEE SNT EG-cys; Anti-NALP1, anti-IL-1β, anti-IL-18, anti-caspase-1, and anti-caspase-11; parthenolide; estrogen binding B-box proteins, COP, ICEBERG, and Z-WEHD-FMK; Ac-Tyr-Val-Ala-Asp-CHO (Ac-YVAD-CHO) or N-acetyl-L-tyrosyl-L-valyl-N-[(1S)-1-(carboxymethyl)-3-chloro-2-oxo-propyl]-L-alaninamide (Ac-YVAD-CMK); Caspase-12 inhibitors; cellular PYRIN domain (PYD)-ony proteins (POP) family: cPOP1 and cPOP2; serpin proteinase inhibitor 9 (PI-9); BCL-2 and BCL-xL; auranofin; PYD homologs M13L-PYD, S013L, SPI-2 homologs CrmA, Serp2, SPI-2, NS1, Kaposi Sarcoma-associated Herpesvirus Orf63; potassium chloride; L-3-trans-(Propylcarbamoyl)oxirane-2-Carbonyl)-L-Isoleucyl-L-Proline Methyl Ester (“CA-074 Me”); Cytochalsin D; N-acetyl-L-cysteine (NAC), (2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate (APDC); cellular pyrin domain (PYD) superfamily proteins, also known as M013; Z-VAD-FMK; colchicine; an isolated double-stranded RNA molecule that inhibits expression of NLRP3, and which can be conjugated to cholesterol or not, and at least one strand including the sequence: GUUUGACUAUCUGUUCUdTdT (SEQ ID NO: 7); an isolated double-stranded RNA molecule that inhibits expression of PYCARD, at least one strand of which includes the sequence of: 5′-GAAGCUCUUCAGUUUCAdTdT-3′ (SEQ ID NO: 12); and an isolated double-stranded RNA molecule that inhibits expression of PYCARD, at least one strand of which includes a sequence selected from: 5′-GAAGCUCUUCAGUUUCAdTdT-3′ (SEQ ID NO: 12); 5′-GGCUGCUGGAUGCUCUGUACGGGAA-3′ (SEQ ID NO: 13); and 5′-UUCCCGUACAGAGCAUCCAGCAGCC-3′ (SEQ ID NO: 14)."],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the inflammasome inhibitor is selected from the group consisting of an inflammosome inhibitor comprising a sequence selected from the sequences of SEQ ID NOS: 7-16; an inhibitor of Caspase-1 selected from VX-765, ML132, VX-740, VRT-018858, YVAD, WEHD; and a Caspase-1 inhibitor comprising the sequence of SEQ ID NO: 17."],"number":10,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 9, wherein the inhibitor is administered by intravitreous injection; subretinal injection; episcleral injection; sub-Tenon's injection; retrobulbar injection; peribulbar injection; topical eye drop application; release from a sustained release implant device that is sutured to or attached to or placed on the sclera, or injected into the vitreous humor, or injected into the anterior chamber, or implanted in the lens bag or capsule; oral administration; or intravenous administration."],"number":11,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the inhibiting IL-18 comprises administering an IL-18 inhibitor."],"number":12,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 12, wherein the IL-18 inhibitor is selected from the group consisting of a neutralizing antibody against IL-18; an antibody that blocks IL-18 binding to the IL-18 receptor, IL-18 neutralizing antibodies; IL-18 binding protein; and IL18BP."],"number":13,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 13, wherein the inhibitor is administered by intravitreous injection; subretinal injection; episcleral injection; sub-Tenon's injection; retrobulbar injection; peribulbar injection; topical eye drop application; release from a sustained release implant device that is sutured to or attached to or placed on the sclera, or injected into the vitreous humor, or injected into the anterior chamber, or implanted in the lens bag or capsule; oral administration; or intravenous administration."],"number":14,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the inhibiting VDAC1 comprises administering a VDAC1 inhibitor and inhibiting VDAC2 comprises administering a VDAC2 inhibitor."],"number":15,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 15, wherein the VDAC1 inhibitor is selected from the group consisting of a VDAC1 inhibitor comprising the sequence of SEQ ID NO: 47; a VDAC2 inhibitor comprising the sequence of SEQ ID NO: 48; phosphorothioate oligonucleotide randomer (Trilink Industries) that inhibits VDAC; cyclosporin A; superoxide dismutase 1; 4,4′-diisothiocyanatostilbene-2,2′-disulfonic acid (DIDS); Bcl-x(L) BH4(4-23); and TRO19622."],"number":16,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 15, wherein the inhibitor is administered by intravitreous injection; subretinal injection; episcleral injection; sub-Tenon's injection; retrobulbar injection; peribulbar injection; topical eye drop application; release from a sustained release implant device that is sutured to or attached to or placed on the sclera, or injected into the vitreous humor, or injected into the anterior chamber, or implanted in the lens bag or capsule; oral administration; or intravenous administration."],"number":17,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the inhibiting Caspase-8 comprises administering a Caspase-8 inhibitor."],"number":18,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 18, wherein the Caspase-8 inhibitor is selected from the group consisting of Z-IETD-FMK, Ac-Ala-Ala-Val-Ala-Leu-Leu-Pro-Ala-Val-Leu-Leu-Ala-Leu-Leu-Ala-Pro-Ile-Glu-Thr-Asp-CHO, Z-Ile-Glu(OMe)-Thr-Asp(OMe)-CH2F, and Cellular fas-associated death domain-like interleukin-1-β-converting enzyme-inhibitory protein (L)."],"number":19,"annotation":false,"title":false,"claim":true},{"lines":["The method of any one of claim 18, wherein the inhibitor is administered by intravitreous injection; subretinal injection; episcleral injection; sub-Tenon's injection; retrobulbar injection; peribulbar injection; topical eye drop application; release from a sustained release implant device that is sutured to or attached to or placed on the sclera, or injected into the vitreous humor, or injected into the anterior chamber, or implanted in the lens bag or capsule; oral administration; or intravenous administration."],"number":20,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the inhibiting NFkB comprises administering a NFkB inhibitor."],"number":21,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 21, wherein the inhibitor is administered by intravitreous injection; subretinal injection; episcleral injection; sub-Tenon's injection; retrobulbar injection; peribulbar injection; topical eye drop application; release from a sustained release implant device that is sutured to or attached to or placed on the sclera, or injected into the vitreous humor, or injected into the anterior chamber, or implanted in the lens bag or capsule; oral administration; or intravenous administration."],"number":22,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the cell is in a subject."],"number":23,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 23, wherein the subject has age-related macular degeneration."],"number":24,"annotation":false,"title":false,"claim":true},{"lines":["An molecule selected from the group consisting of:\n
an isolated double-stranded RNA molecule that inhibits expression of MyD88, wherein a first strand of the double-stranded RNA comprises a sequence selected from SEQ ID NO: 3, 4, 5, 6, and 56, and including about 11 to 27 nucleotides;\n
an isolated double-stranded RNA molecule that inhibits expression of NLRP3 and/or PYCARD, wherein a first strand of the double-stranded RNA comprises a sequence selected from SEQ ID NO: 7-14, and including about 11 to 27 nucleotides;\n
an isolated double-stranded RNA molecule that inhibits expression of Pyrin, comprising the sequence of SEQ ID NO: 15, and including about 11 to 27 nucleotides;\n
an isolated double-stranded RNA molecule that inhibits expression of NALP3, comprising the sequence of SEQ ID NO: 16, and including about 11 to 27 nucleotides;\n
an isolated double-stranded RNA molecule that inhibits expression of caspase-1, comprising the sequence of SEQ ID NO: 17, and including about 11 to 27 nucleotides;\n
an isolated double-stranded RNA molecule that inhibits expression of VDAC1 and/or VDAC2, wherein a first strand of the double-stranded RNA comprises a sequence selected from SEQ ID NO: 47 and 48, and including about 11 to 27 nucleotides;\n
a polypeptide molecule that inhibits MyD88, comprising a sequence selected from SEQ ID NO: 60 and SEQ ID NO: 61."],"number":25,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}